CovidFranceV1, Main, Curation, bibRecord, 001166

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.

Identifieur interne : 001166 ( Main/Curation ); précédent : 001165; suivant : 001167

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.

Auteurs : Evandro De Azambuja [Belgique] ; Dario Trapani [Italie] ; Sibylle Loibl [Allemagne] ; Suzette Delaloge [France] ; Elzbieta Senkus [Pologne] ; Carmen Criscitiello [Italie] ; Philip Poortman [Belgique] ; Michael Gnant [Autriche] ; Serena Di Cosimo [Italie] ; Javier Cortes [Espagne] ; Fatima Cardoso [Portugal] ; Shani Paluch-Shimon [Israël] ; Giuseppe Curigliano [Italie]

Source :

ESMO open [ 2059-7029 ] ; 2020.

RBID : pubmed:32439716

Descripteurs français

KwdFr :
- Betacoronavirus (MeSH), Femelle (MeSH), Humains (MeSH), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Oncologie chirurgicale (méthodes), Pandémies (MeSH), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Priorités en santé (MeSH), Radio-oncologie (méthodes), Santé publique (MeSH), Tumeurs du sein (diagnostic), Tumeurs du sein (thérapie), Télémédecine (méthodes).
MESH :
- diagnostic : Tumeurs du sein.
- méthodes : Oncologie chirurgicale, Radio-oncologie, Télémédecine.
- thérapie : Tumeurs du sein.
- virologie : Infections à coronavirus, Pneumopathie virale.
- épidémiologie : Infections à coronavirus, Pneumopathie virale.
- Betacoronavirus, Femelle, Humains, Pandémies, Priorités en santé, Santé publique.

English descriptors

KwdEn :
- Betacoronavirus (MeSH), Breast Neoplasms (diagnosis), Breast Neoplasms (therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (virology), Female (MeSH), Health Priorities (MeSH), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (epidemiology), Pneumonia, Viral (virology), Public Health (MeSH), Radiation Oncology (methods), Surgical Oncology (methods), Telemedicine (methods).
MESH :
- diagnosis : Breast Neoplasms.
- epidemiology : Coronavirus Infections, Pneumonia, Viral.
- methods : Radiation Oncology, Surgical Oncology, Telemedicine.
- therapy : Breast Neoplasms.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, Female, Health Priorities, Humans, Pandemics, Public Health.

Abstract

The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes.The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice.We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine.The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes.

DOI: 10.1136/esmoopen-2020-000793
PubMed: 32439716
PubMed Central: PMC7295852

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001166

Links to Exploration step

pubmed:32439716

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.</title>
<author><name sortKey="De Azambuja, Evandro" sort="De Azambuja, Evandro" uniqKey="De Azambuja E" first="Evandro" last="De Azambuja">Evandro De Azambuja</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Brussels</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Trapani, Dario" sort="Trapani, Dario" uniqKey="Trapani D" first="Dario" last="Trapani">Dario Trapani</name>
<affiliation wicri:level="1"><nlm:affiliation>European Institute of Oncology (IEO) IRCCS, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>European Institute of Oncology (IEO) IRCCS, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name>
<affiliation wicri:level="1"><nlm:affiliation>GBG Forschungs GmbH, Neu-Isenburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>GBG Forschungs GmbH, Neu-Isenburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name>
<affiliation wicri:level="1"><nlm:affiliation>Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Senkus, Elzbieta" sort="Senkus, Elzbieta" uniqKey="Senkus E" first="Elzbieta" last="Senkus">Elzbieta Senkus</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Criscitiello, Carmen" sort="Criscitiello, Carmen" uniqKey="Criscitiello C" first="Carmen" last="Criscitiello">Carmen Criscitiello</name>
<affiliation wicri:level="1"><nlm:affiliation>European Institute of Oncology IRCCS, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>European Institute of Oncology IRCCS, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poortman, Philip" sort="Poortman, Philip" uniqKey="Poortman P" first="Philip" last="Poortman">Philip Poortman</name>
<affiliation wicri:level="1"><nlm:affiliation>Iridium Kankernetwerk and University of Antwerp, Antwerp, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Iridium Kankernetwerk and University of Antwerp, Antwerp</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gnant, Michael" sort="Gnant, Michael" uniqKey="Gnant M" first="Michael" last="Gnant">Michael Gnant</name>
<affiliation wicri:level="1"><nlm:affiliation>Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Comprehensive Cancer Center, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Di Cosimo, Serena" sort="Di Cosimo, Serena" uniqKey="Di Cosimo S" first="Serena" last="Di Cosimo">Serena Di Cosimo</name>
<affiliation wicri:level="1"><nlm:affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cortes, Javier" sort="Cortes, Javier" uniqKey="Cortes J" first="Javier" last="Cortes">Javier Cortes</name>
<affiliation wicri:level="1"><nlm:affiliation>IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona); Vall d'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona); Vall d'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cardoso, Fatima" sort="Cardoso, Fatima" uniqKey="Cardoso F" first="Fatima" last="Cardoso">Fatima Cardoso</name>
<affiliation wicri:level="1"><nlm:affiliation>Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.</nlm:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Paluch Shimon, Shani" sort="Paluch Shimon, Shani" uniqKey="Paluch Shimon S" first="Shani" last="Paluch-Shimon">Shani Paluch-Shimon</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem, Israel.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Curigliano, Giuseppe" sort="Curigliano, Giuseppe" uniqKey="Curigliano G" first="Giuseppe" last="Curigliano">Giuseppe Curigliano</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy giuseppe.curigliano@ieo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
<wicri:regionArea>Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32439716</idno>
<idno type="pmid">32439716</idno>
<idno type="doi">10.1136/esmoopen-2020-000793</idno>
<idno type="pmc">PMC7295852</idno>
<idno type="wicri:Area/Main/Corpus">001166</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001166</idno>
<idno type="wicri:Area/Main/Curation">001166</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001166</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.</title>
<author><name sortKey="De Azambuja, Evandro" sort="De Azambuja, Evandro" uniqKey="De Azambuja E" first="Evandro" last="De Azambuja">Evandro De Azambuja</name>
<affiliation wicri:level="1"><nlm:affiliation>Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Brussels</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Trapani, Dario" sort="Trapani, Dario" uniqKey="Trapani D" first="Dario" last="Trapani">Dario Trapani</name>
<affiliation wicri:level="1"><nlm:affiliation>European Institute of Oncology (IEO) IRCCS, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>European Institute of Oncology (IEO) IRCCS, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name>
<affiliation wicri:level="1"><nlm:affiliation>GBG Forschungs GmbH, Neu-Isenburg, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>GBG Forschungs GmbH, Neu-Isenburg</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Delaloge, Suzette" sort="Delaloge, Suzette" uniqKey="Delaloge S" first="Suzette" last="Delaloge">Suzette Delaloge</name>
<affiliation wicri:level="1"><nlm:affiliation>Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Senkus, Elzbieta" sort="Senkus, Elzbieta" uniqKey="Senkus E" first="Elzbieta" last="Senkus">Elzbieta Senkus</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.</nlm:affiliation>
<country xml:lang="fr">Pologne</country>
<wicri:regionArea>Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Criscitiello, Carmen" sort="Criscitiello, Carmen" uniqKey="Criscitiello C" first="Carmen" last="Criscitiello">Carmen Criscitiello</name>
<affiliation wicri:level="1"><nlm:affiliation>European Institute of Oncology IRCCS, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>European Institute of Oncology IRCCS, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Poortman, Philip" sort="Poortman, Philip" uniqKey="Poortman P" first="Philip" last="Poortman">Philip Poortman</name>
<affiliation wicri:level="1"><nlm:affiliation>Iridium Kankernetwerk and University of Antwerp, Antwerp, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Iridium Kankernetwerk and University of Antwerp, Antwerp</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gnant, Michael" sort="Gnant, Michael" uniqKey="Gnant M" first="Michael" last="Gnant">Michael Gnant</name>
<affiliation wicri:level="1"><nlm:affiliation>Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.</nlm:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Comprehensive Cancer Center, Medical University of Vienna, Vienna</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Di Cosimo, Serena" sort="Di Cosimo, Serena" uniqKey="Di Cosimo S" first="Serena" last="Di Cosimo">Serena Di Cosimo</name>
<affiliation wicri:level="1"><nlm:affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cortes, Javier" sort="Cortes, Javier" uniqKey="Cortes J" first="Javier" last="Cortes">Javier Cortes</name>
<affiliation wicri:level="1"><nlm:affiliation>IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona); Vall d'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid, Spain.</nlm:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona); Vall d'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Cardoso, Fatima" sort="Cardoso, Fatima" uniqKey="Cardoso F" first="Fatima" last="Cardoso">Fatima Cardoso</name>
<affiliation wicri:level="1"><nlm:affiliation>Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.</nlm:affiliation>
<country xml:lang="fr">Portugal</country>
<wicri:regionArea>Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Paluch Shimon, Shani" sort="Paluch Shimon, Shani" uniqKey="Paluch Shimon S" first="Shani" last="Paluch-Shimon">Shani Paluch-Shimon</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem, Israel.</nlm:affiliation>
<country xml:lang="fr">Israël</country>
<wicri:regionArea>Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Curigliano, Giuseppe" sort="Curigliano, Giuseppe" uniqKey="Curigliano G" first="Giuseppe" last="Curigliano">Giuseppe Curigliano</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy giuseppe.curigliano@ieo.it.</nlm:affiliation>
<country wicri:rule="url">Italie</country>
<wicri:regionArea>Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">ESMO open</title>
<idno type="eISSN">2059-7029</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (MeSH)</term>
<term>Breast Neoplasms (diagnosis)</term>
<term>Breast Neoplasms (therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (virology)</term>
<term>Female (MeSH)</term>
<term>Health Priorities (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Public Health (MeSH)</term>
<term>Radiation Oncology (methods)</term>
<term>Surgical Oncology (methods)</term>
<term>Telemedicine (methods)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Oncologie chirurgicale (méthodes)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Priorités en santé (MeSH)</term>
<term>Radio-oncologie (méthodes)</term>
<term>Santé publique (MeSH)</term>
<term>Tumeurs du sein (diagnostic)</term>
<term>Tumeurs du sein (thérapie)</term>
<term>Télémédecine (méthodes)</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radiation Oncology</term>
<term>Surgical Oncology</term>
<term>Telemedicine</term>
</keywords>
<keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Oncologie chirurgicale</term>
<term>Radio-oncologie</term>
<term>Télémédecine</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term>
<term>Female</term>
<term>Health Priorities</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Public Health</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Betacoronavirus</term>
<term>Femelle</term>
<term>Humains</term>
<term>Pandémies</term>
<term>Priorités en santé</term>
<term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes.The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice.We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine.The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32439716</PMID>
<DateCompleted><Year>2020</Year>
<Month>06</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>06</Month>
<Day>23</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2059-7029</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>5</Volume>
<Issue>Suppl 3</Issue>
<PubDate><Year>2020</Year>
<Month>05</Month>
</PubDate>
</JournalIssue>
<Title>ESMO open</Title>
<ISOAbbreviation>ESMO Open</ISOAbbreviation>
</Journal>
<ArticleTitle>ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">e000793</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1136/esmoopen-2020-000793</ELocationID>
<Abstract><AbstractText>The global preparedness and response to the rapid escalation to severe acute respiratory syndrome coronavirus (SARS-CoV)-2-related disease (COVID-19) to a pandemic proportion has demanded the formulation of a reliable, useful and evidence-based mechanism for health services prioritisation, to achieve the highest quality standards of care to all patients. The prioritisation of high value cancer interventions must be embedded in the agenda for the pandemic response, ensuring that no inconsistency or discrepancy emerge in the health planning processes.The aim of this work is to organise health interventions for breast cancer management and research in a tiered framework (high, medium, low value), formulating a scheme of prioritisation per clinical cogency and intrinsic value or magnitude of benefit. The public health tools and schemes for priority setting in oncology have been used as models, aspiring to capture clinical urgency, value in healthcare, community goals and fairness, while respecting the principles of benevolence, non-maleficence, autonomy and justice.We discuss the priority health interventions across the cancer continuum, giving a perspective on the role and meaning to maintain some services (undeferrable) while temporarily abrogate some others (deferrable). Considerations for implementation and the essential link to pre-existing health services, especially primary healthcare, are addressed, outlining a framework for the development of effective and functional services, such as telemedicine.The discussion covers the theme of health systems strategising, and why oncology care, in particular breast cancer care, should be maintained in parallel to pandemic control measures, providing a pragmatic clinical model within the broader context of public healthcare schemes.</AbstractText>
<CopyrightInformation>© Author (s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>de Azambuja</LastName>
<ForeName>Evandro</ForeName>
<Initials>E</Initials>
<Identifier Source="ORCID">0000-0001-9501-4509</Identifier>
<AffiliationInfo><Affiliation>Institut Jules Bordet and l'Université Libre de Bruxelles (U.LB), Brussels, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y" EqualContrib="Y"><LastName>Trapani</LastName>
<ForeName>Dario</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>European Institute of Oncology (IEO) IRCCS, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Loibl</LastName>
<ForeName>Sibylle</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>GBG Forschungs GmbH, Neu-Isenburg, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Delaloge</LastName>
<ForeName>Suzette</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Oncology, Gustave Roussy and Paris-Saclay University, Villejuif, Île-de-France, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Senkus</LastName>
<ForeName>Elzbieta</ForeName>
<Initials>E</Initials>
<AffiliationInfo><Affiliation>Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Criscitiello</LastName>
<ForeName>Carmen</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>European Institute of Oncology IRCCS, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Poortman</LastName>
<ForeName>Philip</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Iridium Kankernetwerk and University of Antwerp, Antwerp, Belgium.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gnant</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Di Cosimo</LastName>
<ForeName>Serena</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cortes</LastName>
<ForeName>Javier</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>IOB, Institute of Oncology, Quiron Group (Madrid & Barcelona); Vall d'Hebron institute of Oncology (VHIO) (Barcelona), Barcelona, Madrid, Spain.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cardoso</LastName>
<ForeName>Fatima</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Paluch-Shimon</LastName>
<ForeName>Shani</ForeName>
<Initials>S</Initials>
<Identifier Source="ORCID">0000-0002-6677-2199</Identifier>
<AffiliationInfo><Affiliation>Division of Oncology, Shaare Zedek Medical Centre, Jerusalem, Jerusalem, Israel.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Curigliano</LastName>
<ForeName>Giuseppe</ForeName>
<Initials>G</Initials>
<Identifier Source="ORCID">0000-0003-1781-2518</Identifier>
<AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, University of Milano and European Institute of Oncology, IRCCS, Milano, Italy giuseppe.curigliano@ieo.it.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017065">Practice Guideline</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>ESMO Open</MedlineTA>
<NlmUniqueID>101690685</NlmUniqueID>
<ISSNLinking>2059-7029</ISSNLinking>
</MedlineJournalInfo>
<SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName>
<SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="Y">Betacoronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006292" MajorTopicYN="N">Health Priorities</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018787" MajorTopicYN="N">Radiation Oncology</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000071077" MajorTopicYN="N">Surgical Oncology</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017216" MajorTopicYN="N">Telemedicine</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword>
<Keyword MajorTopicYN="Y">ESMO adapted recommendations</Keyword>
<Keyword MajorTopicYN="Y">breast cancer</Keyword>
</KeywordList>
<CoiStatement>Competing interests: GC has received honoraria from Pfizer, Novartis, Eli Lilly, Roche; fees for expert testimony and medical education from Pfizer and has participated in advisory boards for Pfizer, Roche, Eli Lilly, Novartis, Seattle Genetics, Celltrion. SD reports grants, institutional fees from Roche/Genentech, Pfizer, Puma, AstraZeneca, Novartis, Amgen, Sanofi, Eli Lilly, MSD, BMS, Daichi and non-financial support from Roche/Genentech, Pfizer, AstraZeneca. SDC has received fees for medical education from Novartis and Pierre-Fabre and is the recipient of the IG 20774 of Fondazione AIRC. MG reports personal fees/travel support from Amgen, AstraZeneca, Celgene, Eli Lilly, Invectys, Pfizer, Novartis, Puma, Nanostring, Roche, Medison, LifeBrain, all outside the submitted work; an immediate family member is employed by Sandoz. PP is medical advisor of Sordina IORT Technologies. ES has received honoraria from Amgen, AstraZeneca, Clinigen, Egis, Eli Lilly, Genomic Health, Novartis, Pfizer, Pierre-Fabre, Roche, Sandoz, TLC Biopharmaceuticals and travel support from Amgen, AstraZeneca, Egis, Novartis, Pfizer, Roche. FC has consultancy role for Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Sanofi, Samsung Bioepis, Seattle Genetics, Teva. EdA honoraria and/or advisory board from Roche/GNE, Novartis, SeaGen and Zodiac; travel grants from Roche/GNE and GSK/Novartis; research grant to the institution from Roche/GNE, AstraZeneca, GSK/Novartis and Servier. CC declares consultancy/advisory role/speaker's bureau: Pfizer, Eli Lilly, Roche, Novartis. SP-S discloses honoraria, consultancy and speaker’s bureau: Roche, Novartis, Pfizer, Eli Lilly, AstraZeneca, Nanostring.</CoiStatement>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>04</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>04</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>5</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>6</Month>
<Day>9</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32439716</ArticleId>
<ArticleId IdType="pii">esmoopen-2020-000793</ArticleId>
<ArticleId IdType="doi">10.1136/esmoopen-2020-000793</ArticleId>
<ArticleId IdType="pmc">PMC7295852</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Clin Oncol. 2009 May 20;27(15):2466-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19349544</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Oncol. 2018 Apr 10;36(11):1073-1079</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29443653</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Oncol (R Coll Radiol). 2020 May;32(5):279-281</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32241520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2015 Mar;16(3):266-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25637340</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Clin Oncol. 2020 May;17(5):268-270</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32242095</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2019 Oct 1;30(10):1674</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31236598</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Cancer. 2020 Jun;132:8-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32305011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2003 Aug;14(8):1215-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12881382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2017 Oct 1;28(10):2340-2366</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28945867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 21;382(21):2049-2055</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32202722</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Breast Cancer. 2018 Jun;18(3):205-213</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28781022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2019 Jun 29;393(10191):2599-2612</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31178152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Crit Care. 2018 Dec 4;22(1):326</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30514339</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2020 Feb;31(2):171-190</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31959335</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Apr 18;395(10232):1253-1254</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32246914</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Public Health. 2014 Jul 29;2:87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25121080</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Breast Care (Basel). 2019 Aug;14(4):185-187</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31558891</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Breast Cancer (Dove Med Press). 2017 Mar 13;9:141-152</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28331365</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2018 Jun 2;391(10136):2236-2271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29893224</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2012 Apr 26;344:e2718</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22539013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2020 Mar;21(3):335-337</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32066541</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Oncol. 2020 May;21(5):629-630</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32247319</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Health Qual Life Outcomes. 2017 Oct 19;15(1):206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29052503</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>CA Cancer J Clin. 2018 Mar;68(2):153-165</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29338071</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2017 Mar 18;389(10074):1134-1150</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27865536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Thromb Haemost. 2020 May;18(5):1094-1099</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220112</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidFranceV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001166 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001166 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidFranceV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:32439716
   |texte=   ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i   -Sk "pubmed:32439716" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidFranceV1

This area was generated with Dilib version V0.6.37.
Data generation: Tue Oct 6 23:31:36 2020. Site generation: Fri Feb 12 22:48:37 2021

	Serveur d'exploration sur la COVID en France
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la COVID en France

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.

ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki